FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.

FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.

FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.

VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

FDW028 is a highly potent and selective inhibitor of FUT8. FDW028 demonstrates strong anti-tumor effects by promoting defucosylation and inducing lysosomal degradation of B7-H3 via the chaperone-mediated autophagy (CMA) pathway. Additionally, FDW028 suppresses the AKT/mTOR signaling pathway. FDW028 exhibits potent anti-Metastatic colorectal cancer (mCRC) activities.

VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

VVD-130037(BAY-3605349) is an orally available covalent small molecule activator of Kelch-like ECH associated protein 1 (KEAP1), which provide enhanced cellular degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2) resulting in significant inhibition of tumor growth in advanced solid tumors.

NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.

NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model.